Allison Ron R, Sibata Claudio H
PDT Center and Department of Radiation Oncology, Brody School of Medicine at East Carolina University, Greenville, 600 Moye Boulevard LJCC 172, NC 27858, USA.
Photodiagnosis Photodyn Ther. 2008 Jun;5(2):112-9. doi: 10.1016/j.pdpdt.2008.05.004. Epub 2008 Jun 24.
Photodynamic therapy (PDT) is an innovative minimally invasive therapy that has great potential for both tumor ablation and normal tissue preservation. However, while in recent years the standards of surgery, radiation and chemotherapy have dramatically improved in terms of outcomes and morbidity, the same cannot be said of PDT in general and Photofrin((R))-based PDT in particular. As currently practiced PDT dosimetry has not really improved tumor ablation and diminished side effects over reports from two decades ago. We critically examine the clinical variables available for PDT dosimetry and conclude that the simple maneuver of diminishing drug dose, with an appropriate increase in light dose, can enhance disease control with a significantly lower risk of morbidity. This conclusion should also be applicable to most systemically introduced photosensitizer.
光动力疗法（PDT）是一种创新的微创疗法，在肿瘤消融和正常组织保留方面具有巨大潜力。然而，近年来，手术、放疗和化疗的标准在治疗效果和发病率方面有了显著提高，但总体而言，光动力疗法，尤其是基于卟吩姆钠（Photofrin®）的光动力疗法并非如此。就目前的实际应用情况而言，光动力疗法的剂量测定在肿瘤消融方面并未真正取得进展，与二十年前的报告相比，副作用也没有减少。我们严格审查了可用于光动力疗法剂量测定的临床变量，并得出结论：简单地减少药物剂量，并适当增加光剂量，能够在显著降低发病风险的情况下加强疾病控制。这一结论也应适用于大多数全身给药的光敏剂。
